

## **Are The Proton Pump Inhibitor-Responsive And Non-Responsive Phenotypes Of Eosinophilic Esophagitis Exactly The Same?**

Gómez Torrijos E<sup>1</sup>, Castro Jimenez A<sup>1</sup>, Gratacós Gómez AR<sup>2</sup>, González Jiménez OM<sup>2</sup>, Joyanes Romo JB<sup>2</sup>, Feo Brito F<sup>2</sup>, Urra Ardanaz JM<sup>3</sup>, García Rodríguez R<sup>3</sup>

<sup>1</sup>Allergy Section, Hospital General Universitario, Ciudad Real

<sup>2</sup>Facultad de Medicina, Universidad de Castilla La Mancha, Ciudad Real

<sup>3</sup>Immunology Section, Hospital General Universitario, Ciudad Real

### **Corresponding autor**

Elisa Gómez Torrijos

Address: C/Obispo R. Torija s/n. 13005. Ciudad Real

E-mail: egomez.t.cr@gmail.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:

10.18176/jiaci.0666

**Key Words:** Eosinophilic esophagitis. Phenotypes. Proton pump inhibitor. Allergic characteristics. Atopic comorbidities.

**Palabras clave:** Esofagitis eosinofílica. Fenotipos. Inhibidor de la bomba de protones. Características alérgicas. Comorbilidades atópicas.

A new conceptual definition of eosinophilic esophagitis (EoE) was proposed in the 2011 consensus and a new potential disease phenotype, the proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) was also recognized [1]. EoE was defined as a clinicopathological condition, antigen driven, characterized clinically by symptoms of esophageal dysfunction and histologically by  $\geq 15$  eosinophils per high power field (eos/hpf), and after a comprehensive assessment of non-EoE disorders that could cause esophageal eosinophilia [2]

EoE and PPI-REE were considered separate clinical entities as they showed a different response to the PPI trial. Later, the experts proposed not to include the responsiveness to a PPI as a diagnostic criterion and, consequently, avoiding the term PPI-REE for those subjects that have an EoE phenotype with both histological and clinical response to PPI therapy [3]. Currently, they advise to call these two phenotypes as responding EoE (R-EoE) and not responding EoE to PPI (NR-EoE).

Although not all experts agree, recent and evolving evidence, mostly from adults, shows that PPI-REE and EoE patients are clinically, endoscopically and histologically indistinguishable, with features of Th2 immune-mediated inflammation and gene expression [3]. A Spanish study concludes that, both phenotypes of EoE share sensitization profiles with only slight differences [4]

There are few any studies on whether both phenotypes (R-EoE and NR-EoE), are identical in allergic characteristics (ACh) and atopic comorbidities (AC). The objectives of this study were to study the similarities and differences between both phenotypes regarding the ACh and AC.

This was a prospective observational study that included patients diagnosed with EoE (symptoms of esophageal dysfunction and  $\geq 15$  eos / hpf in at least one esophageal biopsy), from 2013-2018. All completed a 2 months treatment with omeprazole 40 mgs b.i.d. Subsequently, an esophagoscopy with sectional biopsies was performed to each patient to see if the EoE had remitted with PPI therapy.

In both subgroups (R-EoE and NR-EoE), the following variables were studied and compared: skin prick tests (SPT) for aeroallergens (mites, fungi, epithelia and pollens) and foods (wheat, cow's milk (CM), eggs, lentils, peanuts, hake and shrimp), total IgE (tIgE), specific Ig E (sIgE) to the mentioned foods, eosinophils in peripheral blood (EPB), eosinophil cationic protein (ECP), atopy (at least 1 positive allergological test (SPT > 3.3 mm or sIg E > 0.35 kU / L) and atopic

comorbidities(AC) such as atopic dermatitis (AD), rhinoconjunctivitis (RC), bronchial asthma (BA) and IgE-mediated food allergy (Ig E-FA).

Statistical study: Comparison between the two groups were made using the Student's t-test for quantitative variables and the Chi square test for qualitative variables, since patient samples from both phenotypes followed a normal distribution. Statistics study were performed using a SPSS package.

Treatment with omeprazole was prescribed to 203 patients diagnosed with EoE, but 27 left the study for breach or refusing of esophagoscopies. EoE remitted only in 55 patients (31.25%)

Significant differences were found between both groups in the following variables: tests to animal dander:(p:0.025), sIgE to CM:(p:0.045) IgE-FA:(p:0.024), EPB:(p:0.021), atopy:(p:0.002, 50% and AC:(p:0.001) (Table 1). We did not find significant differences between both phenotypes in sensitization to the rest of aeroallergens or other foods except to egg that was at the limit of statistical significance.

Although most experts in EoE agree that the management of this disease should be multidisciplinary [5] but there is hardly any scientific study on allergological characteristics in both EoE phenotypes, probably, because the experts did not consider it relevant, but it is known that AC (DA, RC, BA and IgE-FA) are positively associated with EoE diagnosis and, possibly, it might be a late manifestation of the allergic march [6]

There were no significant differences between the patients with R-EoE and NR-EoE regarding total IgE or sensitizations to aeroallergens except for sensitization to epithelia and CM; if we compare our results with those of a study in a Japanese population [7], where they compared total IgE level in both EoE phenotypes, they found differences in the levels of this biomarker, being higher in NR-EoE; This difference with our results could be explained because the number of patients in our study is much smaller and because the authors do not specify whether they were sensitized to seasonal/perennial aeroallergens.

Pollen sensitization is the most frequent one in our EoE patients, but we did not find differences between both subgroups in this variable. These results agree with those of other published studies [8]; which could be explained because in the area where the patients in our study live, the levels of grass pollens and olive trees in spring are very high.

The results of the differences in sIgE levels to CM support a higher atopic burden in patients with R-EoE; in addition, in a study found that BA and IgE-FA, were independently and cumulatively associated with more EoE diagnoses [6]

In a study done in the US several years ago, there were no differences for total IgE level (9); On the other hand, the authors of this same study did find significant statistical differences in the EPB count which was greater in the NR-EoE subgroup; these results agree with those obtained in our study and with those of the Japanese study previously mentioned [7].

IgE-FA is more frequent in patients with NR-EoE both in our study and in the Japanese one. Our patients have more AC also in this subgroup, while in the Japanese study, they only found that the NR-EoE subgroup had more BA [7]

In studies carried out by allergists, the percentage of patients with R-EoE is lower than in other studies carried out by gastroenterologists (10); these differences could be explained because patients referred from Primary Care to Allergology have more atopy than those referred to other specialties such as pediatrics and / or gastroenterology.

This study compares the atopic characteristics and comorbidities between the two populations, the R-EoE and NR EoE. The results suggest that both phenotypes may not exactly be the same; the NR-EoE phenotype seem to have a greater number of allergic sensitizations and comorbidities. Although more studies with a greater number of patients are needed to confirm these results.

We conclude that NR-EoE may represent a phenotype with a higher degree of atopy.

#### **Conflict of interest**

All authors declare no conflict of interests.

#### **Financial sources**

All authors declare no financial sources.

## References

1. González-Cervera J, Lucendo AJ. Eosinophilic Esophagitis: An Evidence-Based Approach to Therapy. *J Investig Allergol Clin Immunol*. 2016;26(1):8-18
2. Orden Izquierdo E, Gutiérrez Junquera C, Mahillo-Fernández I, Subiza Garrido-Lestache J, Román Riechmann E. Increasing Incidence of Pediatric Eosinophilic Esophagitis in the Southwest of Madrid, Spain. *J Investig Allergol Clin Immunol*. 2019;29(1):24-9
3. Molina-Infante J, Bredenoord AJ, Cheng E, Dellon ES, Furuta ES, Gupta SK, et al. Proton Pump Inhibitor-Responsive Oesophageal Eosinophilia: An Entity Challenging Current Diagnostic Criteria for Eosinophilic Oesophagitis. *Gut*. 2016;65(3):524–31.
4. Lluncor M, Pedrosa M, Cancelliere N, Rivero-Paparoni D, Burgos A, Fiandor A, et al. Molecular Sensitization Profile According to Proton Pump Inhibitor Response in Patients With Esophageal Eosinophilia. *J Investig Allergol Clin Immunol*. 2018;28(5):354-8
5. Reed CC, Dellon ES. Eosinophilic esophagitis. *Med Clin North Am*. 2019;103(1):29–42.
6. Hill DA, Grundmeier RW, Ramos M, and Spergel JM. Eosinophilic Esophagitis is a Late Manifestation of the Allergic March. *J Allergy Clin Immunol Pract*. 2018;6(5):1528–33.
7. Jiao D, Ishimura N, Maruyama R, Ishikawa N, Nagase M, Oshima N, et al. Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients. *J Gastroenterol*. 2017;52:203–21.
8. Letner D, Farris A, Khalili H, Garber J. Pollen-food allergy syndrome is a common allergic comorbidity in adults with eosinophilic esophagitis. *Dis Esophagus*. 2018;31(2):10.
9. Dellon ES, Speck O, Woodward K, Gebhart JH, Madanick RD, Levinson S, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: A Prospective Cohort Study. *Am J Gastroenterol*. 2013;108(12):1854–60.
10. Gómez-Torrijos E, García-Rodríguez R, Castro-Jiménez A, Rodríguez-Sánchez J, Méndez Díaz Y, Molina-Infante J. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. *Aliment Pharmacol Ther*. 2016;43(4):534-40.

**Table 1. Variables with significant statistical differences between both subgroups of Eosinophilic esophagitis**

	EoE unresponsive to PPI	EoE responsive to PPI	P
Skin prick test (positive to epitelia)	43.8%	25%	0.025
slg E-Cow milk (kU/L)	0.54	0.24	0.045
Food Allergy	29.6%	12%	0.024
Eosinophils in Peripheral blood/ $\mu$ L	323.66(X)	250.75(X)	0.021
Atopic	75%	50%	0.002
Atopic Comorbidities	77.6%	52,2%	0.001

PPI: Proton pump inhibitors drugs  
P<0.05 (statistical significance)  
X: Arithmetic mean